ISRCTN45338135: Phase I trial: PXL 272092
- Overall trial status
- Deferred
- Recruitment status
- Not yet recruiting
Phase I trial: PXL 272092
The ISRCTN registry has formed a partnership with the Health Research Authority (HRA) on registration of clinical trials. Please see the HRA’s guidance on research registration for further information. If you have any queries, please contact us at info@isrctn.com.
For other ISRCTN news and updates please visit the ISRCTN page at BMC and the What's new page.
The ISRCTN registry is a primary clinical trial registry recognised by WHO and ICMJE that accepts all clinical research studies (whether proposed, ongoing or completed), providing content validation and curation and the unique identification number necessary for publication. All study records in the database are freely accessible and searchable.
ISRCTN supports transparency in clinical research, helps reduce selective reporting of results and ensures an unbiased and complete evidence base.
ISRCTN accepts all studies involving human subjects or populations with outcome measures assessing effects on human health and well-being, including studies in healthcare, social care, education, workplace safety and economic development. The registry welcomes submissions in English from any location. Studies should ideally be registered prospectively (before recruitment starts). ISRCTN also accepts studies registered retrospectively once they are underway or after completion.
Phase I trial: PXL 272092
Hyperpolarised xenon magnetic resonance pulmonary imaging in patients with long COVID (EXPLAIN)
A single-centre, single-blinded, randomized, crossover study to assess the nicotine pharmacokinetic profile following the use of two variants of the commercially available e-cigarette logic compact in adult healthy electronic cigarette users